Search PubMed⌕ Search

Biomedical subjects

A Bismuth

Publications and source records attributed to A Bismuth.

At least 37 records · Page 2Linked to original sources
PubMed1991

[Safety of donors, quality of products, how much to reduce the quantity of citrate].

We examined 1,053 blood samples from 48 donors, for the effect of gradual reduction of citrate. We observed that: 1--Platelet count does not show any significant variation between 1/8 to 1/18 ratio. 2--In 13.3% of the cases, platelet clumping starts at 1/18 ratio. 3--There was no significant variation of the thrombin plasma level between 1/8 to 1/16 ratio (by measuring thrombin/ATIII complex). Our results show clearly that we can reduce the citrate ratio to 1/14 without expecting any adverse effect. Therefore we designated 1/14 as the security ratio. Parallel to this we also found that the average level +/- SD of ionized calcium is 100 +/- 10 muMol at 1/14 ratio.

Adult↗
PubMed1991

[Liver transplantation and the major histocompatibility complex].

We have carried out a retrospective study over 308 liver transplant patients (31 of them have had a retransplantation) in Professor Bismuth's Department at Paul Brousse Hospital. The purpose of the study was a search for the possible effect of donor/recipient major histocompatibility complex on the evolution of the transplantation. We chose to study four parameters: early acute rejection; chronic rejection; retransplantation cases and death frequency; graft survival. We observed the following: for HLA A locus: in cases of total or partial compatibility there are more moderate early acute rejections than in the case of incompatibility (p less than 0.02); for HLA B locus: in the case of total compatibility there are more chronic rejections than in cases of partial or total incompatibility (p less than 0.03); for joint A and B locus: the results are similar to those of A locus (p less than 0.03); for HLA class I: we observed no effect either on graft survival or on retransplantation cases or on death frequency; for HLA DR: we did not find any effect on the studied parameters. Considering the low statistical significance of these results and in order to confirm our analysis, we have started a prospective study in collaboration with two other European Transplantation Centers.

Graft Rejection↗
PubMed1990

Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients.

We have investigated the usefulness of serum hepatitis delta virus (HDV) RNA detection using a slot hybridization analysis of serum samples from ten patients with acute hepatitis and delta markers (group I), from 28 patients with chronic delta hepatitis (group II) and from seven liver graft recipients with hepatitis B virus (HBV) and HDV related cirrhosis or fulminant hepatitis (group III). The slot-blots were hybridized with both HDV-complementary DNA and single-stranded RNA probes. With the single-stranded RNA probe, HDV RNA was detected in the first serum sample available in 9/10 of the patients with acute hepatitis (group I). In addition, HDV RNA was detected in 8/9 and 7/8 of the samples obtained within and after 1 month of the onset of hepatitis. Five of the ten patients scored positive for HDV RNA and negative for hepatitis delta antigen (HDAg) while one was negative for HDV RNA and positive for HDAg. The same RNA probe enabled the detection of serum HDV RNA in 21/28 chronic hepatitis patients (liver HDAg and/or IgM anti-HD positive) (group II). Among the liver graft recipients (group III), 7/7 had a recurrent delta infection. Serum HDAg, liver HDAg and anti-HD IgM were identified in 3/7, 6/7 and 5/7 of the patients, respectively. HDV RNA was detected in the seven patients with either persistent (4/7) or transient (3/7) positivity. In addition, HBsAg and HBV RNA were persistently shown in 4/7 patients with continuous HDV replication. In the remaining three patients, HDV RNA was detectable despite the absence of HBsAg.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1990

Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model.

We have investigated the recurrence of Hepatitis B virus (HBV) in 30 patients treated by orthotopic liver transplantation and given high doses of anti-HBs immunoglobulin. The polymerase chain reaction (PCR) assay showed no evidence of HBV DNA sequences in the liver of 23/24 patients who remained serum HBsAg-negative during a mean follow-up of 13 months (2-24 months) after OLT. However, the liver scored positive in all the 6 individuals in whom HBsAG reappeared. The PCR assay identified HBV DNA sequences in the peripheral blood mononuclear cells of 7 of 11 subjects who were serum HBsAG-negative and liver HBV DNA-negative by PCR. Therefore, this application of the sensitive PCR assay demonstrates persistent infection of PBMC in the absence of liver HBV--thus OLT provides a model for studying the interaction between HBV, PBMC, and the liver.

DNA, Viral↗
PubMed1982

[Approach to cochleovestibular tolerability of aminoglycosides in man. Demonstration of a methodology apropos of a controlled comparative trial of dibekacin versus gentamicin].

A controlled trial comparing the effects of dibekacin and gentamicin in 30 patients has enabled us to standardise the most commonly used vestibulocochlear tests. None of the patients treated with dibekacin showed any auditory disturbance. The only abnormality detected was on vocal audiometry in 7 patients treated with gentamicin. Could vocal audiometry be the first paraclinical test capable of detecting aminoglycoside ototoxicity?

Clinical Trials as Topic↗
PubMed1980

Genetic control of sensitivity to Moloney leukemia virus in mice. III. The three H-2 linked Rmv genes are immune response genes controlling the antiviral antibody response.

It has been shown previously that three different H-2-associated genes control the resistance to viremia and leukemia in Moloney virus-infected mice: Rmv. 1, mapping to the I-A or less probably K regions; Rmv. 2, mapping to the I-C, S or G regions and Rmv. 3, mapping to the D or T regions. Experiments have been performed to determine the role of these genes in the control of the antibody responses directed against Moloney murine leukemia virus (M. MuLV) virions and/or leukemic cells. The inoculation of infectious M.MuLV failed to provide conclusive responses due to unequal replication of the virus in different inbred strains resulting in variable antigenic stimulations and/or in vivo antibody absorptions. The use of inactivated M.MuLV as antigen allowed to avoid these problems. It showed that (2) the IgG-specific antiM.MuLV response is controlled by H-2 linked genes, (b) a clear correlation exists between high or low-responder phenotypes and the resistance or susceptibility to M.MuLV infection and (c) all three Rmv genes behave like immune response genes. These results were not surprising for Rmv. 1 and Rmv. 2 which map in the I region of the major histocompatibility complex. It was more puzzling for Rmv. 3. Further experiments are necessary to determine the exact mechanism by which this gene controls the immune response.

Animals↗
PubMed1974

Relationship between HL-A antigens and beta-2-microglobulin as studied by immunofluorescence on the lymphocyte membrane.

The antibody-induced redistribution of beta2-microglobulin (beta2-micro) and HL-A antigens on the surface of living lymphocytes was studied by immunofluorescence. When all beta2-micro was redistributed on the lymphocyte membrane by specific rabbit antibodies and goat antirabbit Ig conjugates, the HL-A antigens were no more detectable with anti-HL-A conjugates outside the beta2-micro caps already formed. However, the redistribution of HL-A antigens fails to provoke the redistribution of all detectable beta2-micro molecules. These results suggest that HL-A antigens may be associated with beta2-micro at the cell surface, but that all beta2-micro molecules are not bound to HL-A antigens.

Animals↗